Details of the Drug Combinations

General Information of This Drug (ID: DMTQF4A)

• Drug Name: Tenofovir alafenamide (DMTQF4A)
• Synonyms: Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy; Tenofovir; UNII-W4HFE001U5; W4HFE001U5; (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID; (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid; (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-[2-(Phosphonomethoxy)propyl]adenine; (R)-PMPA; ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid; 147127-20-6; 9-[(R)-2-(phosphonomethoxy)propyl]adenine; Apropovir; CHEBI:63625; D,L-Tenofovir; GS-1278; PMPA; PMPA gel; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; 379270-37-8; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE

Indication

HIV infectious disease; ICD 11: N.A.; Status: Approved [1]

List of Combinatorial Drugs (CBD) Containing This Drug

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cobicistat + Tenofovir alafenamide	DCHB3VE	Cobicistat	HIV Infections	[2]
Cobicistat + Tenofovir alafenamide	DC9DNCT	Cobicistat	HIV Infections	[2]
Dolutegravir + Tenofovir alafenamide	DCAWUAP	Dolutegravir	Amyotrophic Lateral Sclerosis	[3]
Emtricitabine + Tenofovir alafenamide	DC2A9FF	Emtricitabine	Human immunodeficiency virus-1 infection	[4]
Emtricitabine + Tenofovir alafenamide	DCJIOQC	Emtricitabine	Human immunodeficiency virus-1 infection	[4]
Emtricitabine + Tenofovir alafenamide	DCA6JSD	Emtricitabine	HIV	[5]
Emtricitabine + Tenofovir alafenamide	DCZ4OHF	Emtricitabine	HIV	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT04518228) Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
• [3] ClinicalTrials.gov (NCT02437110) HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT02904369) PK and PD Study of Oral F/TAF for HIV Prevention
• [6] ClinicalTrials.gov (NCT05979311) A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy